Prostate Cancer Clinical Trial

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Summary

The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

International Prostate Symptom Score (IPSS) ≥ 8
Gleason Grade Group 1-3
Prostate-specific Antigen (PSA) ≤20ng/mL
Cancer stage less than or equal to T2c

Exclusion Criteria:

Patients with previous surgical treatment of benign prostatic hyperplasia
MRI evidence of extracapsular extension of cancer
Any severe illness that would prevent complete study participation or confound study results

Study is for people with:

Prostate Cancer

Estimated Enrollment:

125

Study ID:

NCT06051942

Recruitment Status:

Recruiting

Sponsor:

PROCEPT BioRobotics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

NorthShore University HealthSystem
Glenview Illinois, 60026, United States More Info
Pooja Talaty, MS MHA CCRP
Contact
847-503-4280
[email protected]
Urology Austin, PLLC
Austin Texas, 78745, United States More Info
Jennifer Penshorn, RN
Contact
512-410-3773
[email protected]
The Chinese University of Hong Kong
Hong Kong , , Hong Kong More Info
American University of Beirut
Beirut , , Lebanon More Info
Aline Yacoubian
Contact
+ 961 3 705 235
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

125

Study ID:

NCT06051942

Recruitment Status:

Recruiting

Sponsor:


PROCEPT BioRobotics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.